高分子医薬品CDMOの世界市場

高分子医薬品CDMOの世界市場は2030年までに203億米ドルに達する見込み

2024年に133億米ドルと推定される高分子医薬品CDMOの世界市場は、2024年から2030年にかけてCAGR 7.2%で成長し、2030年には203億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである受託製造サービスは、CAGR 6.0%を記録し、分析期間終了時には125億米ドルに達すると予測されます。開発受託サービス分野の成長率は、分析期間中CAGR 9.4%と推定されます。

米国市場は36億米ドル、中国はCAGR 11.1％で成長すると予測

米国の高分子医薬品CDMO市場は、2024年に36億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに42億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と6.9%と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の高分子医薬品CDMO市場- 主要動向と促進要因のまとめ

高分子医薬品CDMO市場はバイオ医薬品の進歩とともにどのように進化しているか？

高分子医薬品開発製造受託機関（CDMO）市場は、生物学的製剤、バイオシミラー、先進治療に対する需要の増加により、急速な変貌を遂げつつあります。モノクローナル抗体、組換えタンパク質、細胞・遺伝子治療の台頭により、複雑な高分子製造をサポートできる専門的なCDMOサービスへの強いニーズが生まれています。シングルユース・バイオプロセシング技術の開発により、より柔軟でスケーラブルな製造ソリューションが可能になり、医薬品開発企業のコストと納期が短縮されています。さらに、バイオプロセスにおける人工知能と機械学習の統合は、プロセスの最適化、品質管理、予知保全を強化しています。規制当局が生物製剤製造のガイドラインを厳格化する中、CDMOは製品の安全性と有効性を確保するため、高効率の精製技術、分析開発、コンプライアンス重視のワークフローに投資しています。このような業界のダイナミクスの進化により、大型分子CDMOは、医薬品開発と商業化を加速させたいバイオ医薬品企業にとって不可欠なパートナーとして位置づけられています。

なぜ高分子CDMOサービスの需要が増加しているのか？

治療パイプラインにおける生物製剤とバイオシミラーへの依存の高まりにより、高分子CDMOサービスの需要が大幅に増加しています。製薬会社は、CDMOの専門知識、高度なインフラ、規制遵守能力を活用するため、開発・製造業務をCDMOに委託するケースが増えています。発酵、細胞培養、精製工程を含む高分子医薬品の製造は複雑であるため、最先端の設備を備えた高度な技術を持つ受託製造業者の関与が必要となります。さらに、ブロックバスター生物製剤の特許切れによるバイオシミラーの拡大が、プロセス開発とスケールアップ製造におけるCDMOサービスの需要を促進しています。個別化医療や標的生物学的療法といった新たな動向も、製薬会社がカスタマイズされた製造ソリューションを求める中で、市場成長に寄与しています。さらに、世界のサプライチェーンの混乱は、生物製剤製造の継続性を確保するために、弾力的で地理的に多様なCDMOパートナーシップの必要性を浮き彫りにしています。バイオ医薬品の研究開発への投資が増加する中、CDMOは業界の進化するニーズに応える上で重要な役割を果たしています。

高分子CDMOの成長に影響を与える課題とは？

市場の力強い成長にもかかわらず、高分子CDMOは事業拡大や業務効率に影響を与えかねないいくつかの課題に直面しています。主な課題の1つは、クリーンルーム、バイオリアクター、精製システムなど、高度なバイオ医薬品製造施設の設立と維持にかかるコストの高さです。高分子医薬品製造に関する厳しい規制状況は、CDMOが進化するコンプライアンス要件に継続的に適応しなければならないため、業務をさらに複雑にしています。キャパシティーの制約も大きな課題であり、高分子医薬品受託製造の需要の高まりは、利用可能な製造インフラを上回っています。これに対処するため、CDMOは製造拠点を拡大し、モジュラー・バイオプロセシングや連続製造技術などの柔軟な製造プラットフォームに投資しています。高分子の医薬品開発は複雑であるため、高度な分析能力やプロセスの特性評価に関する専門知識も必要となり、技術的課題がさらに増えています。さらに、バイオプロセス・エンジニアリングと規制遵守における人材不足は、CDMOが効率的に事業を拡大する能力に影響を与えています。これらの課題を克服することは、持続可能な成長を確保し、高分子CDMOサービスの需要増に対応する上で極めて重要です。

高分子CDMO市場拡大の原動力は？

高分子CDMO市場の成長は、生物製剤の採用の増加、バイオ医薬品への投資の増加、製造技術の進歩など、いくつかの要因によって牽引されています。モノクローナル抗体、ワクチン、細胞・遺伝子治療薬に対する需要の急増は、複雑なバイオ製造工程に対応できる専門的なCDMOサービスの必要性を後押ししています。製薬会社が医薬品製造のための費用対効果が高く、スケーラブルなソリューションを求めているため、製薬会社とCDMO間の開発受託パートナーシップの拡大が加速しています。規制当局もまた、生物製剤製造における品質、安全性、効率性を促進するガイドラインを制定することで、市場成長を促進する上で重要な役割を果たしています。個別化医療や精密生物製剤に向けた動向の高まりは、シングルユースシステムやハイスループットスクリーニングプラットフォームなどの柔軟な製造技術への投資をCDMOに促しています。さらに、プロセスの自動化、AI主導の分析、スマートバイオプロセシングの進歩が効率を高め、製造コストを削減しています。製薬企業がリスクを軽減し、リソースを最適化するためにアウトソーシングへのシフトを続ける中、高分子CDMO市場は持続的な成長を遂げ、バイオ医薬品製造の未来を形作る態勢が整っています。

セグメント

サービス（受託製造サービス、受託開発サービス）;ソース（哺乳類ソース、微生物ソース、その他ソース）;エンドユーザー（バイオテクノロジー企業エンドユーザー、CROエンドユーザー、その他エンドユーザー）

調査対象企業の例

• Abzena
• AGC Biologics
• Avid Bioservices
• BioVectra
• Boehringer Ingelheim BioXcellence
• Catalent, Inc.
• Emergent BioSolutions
• Eurofins Scientific
• FUJIFILM Diosynth Biotechnologies
• JHL Biotech
• KBI Biopharma
• Lonza Group
• Recipharm AB
• Rentschler Biopharma SE
• Samsung Biologics
• Siegfried Holding AG
• Syngene International
• Thermo Fisher Scientific Inc.
• Wuxi AppTec
• WuXi Biologics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Large Molecule Drug Substance CDMO Market to Reach US$20.3 Billion by 2030

The global market for Large Molecule Drug Substance CDMO estimated at US$13.3 Billion in the year 2024, is expected to reach US$20.3 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Contract Manufacturing Service, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$12.5 Billion by the end of the analysis period. Growth in the Contract Development Service segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 11.1% CAGR

The Large Molecule Drug Substance CDMO market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Large Molecule Drug Substance CDMO Market - Key Trends & Drivers Summarized

How Is the Large Molecule Drug Substance CDMO Market Evolving with Biopharmaceutical Advancements?

The large molecule contract development and manufacturing organization (CDMO) market is undergoing rapid transformation, driven by the increasing demand for biologics, biosimilars, and advanced therapies. The rise of monoclonal antibodies, recombinant proteins, and cell and gene therapies has created a strong need for specialized CDMO services that can support complex large molecule manufacturing. Advancements in single-use bioprocessing technologies are enabling more flexible and scalable production solutions, reducing costs and turnaround times for drug developers. Additionally, the integration of artificial intelligence and machine learning in bioprocessing is enhancing process optimization, quality control, and predictive maintenance. As regulatory agencies tighten guidelines for biologics manufacturing, CDMOs are investing in high-efficiency purification techniques, analytical development, and compliance-driven workflows to ensure product safety and efficacy. These evolving industry dynamics are positioning large molecule CDMOs as indispensable partners for biopharmaceutical companies looking to accelerate drug development and commercialization.

Why Is Demand for Large Molecule CDMO Services Increasing?

The growing reliance on biologics and biosimilars in therapeutic pipelines has significantly increased the demand for large molecule CDMO services. Pharmaceutical companies are increasingly outsourcing development and manufacturing activities to CDMOs to leverage their specialized expertise, advanced infrastructure, and regulatory compliance capabilities. The complexity of large molecule drug manufacturing, including fermentation, cell culture, and purification processes, necessitates the involvement of highly skilled contract manufacturers with state-of-the-art facilities. Additionally, the expansion of biosimilars, driven by patent expirations of blockbuster biologics, has fueled demand for CDMO services in process development and scale-up manufacturing. Emerging trends such as personalized medicine and targeted biologic therapies are also contributing to market growth, as pharmaceutical companies seek customized manufacturing solutions. Furthermore, global supply chain disruptions have highlighted the need for resilient and geographically diverse CDMO partnerships to ensure continuity in biologics production. With increasing investments in biopharmaceutical R&D, CDMOs are playing a crucial role in meeting the industry’s evolving needs.

What Challenges Are Impacting the Growth of Large Molecule CDMOs?

Despite strong market growth, large molecule CDMOs face several challenges that could impact their expansion and operational efficiency. One of the primary challenges is the high cost of establishing and maintaining advanced biopharmaceutical manufacturing facilities, including cleanrooms, bioreactors, and purification systems. The stringent regulatory landscape for large molecule drug manufacturing further complicates operations, as CDMOs must continuously adapt to evolving compliance requirements. Capacity constraints are another significant challenge, with growing demand for large molecule contract manufacturing outpacing available production infrastructure. To address this, CDMOs are expanding their manufacturing footprints and investing in flexible production platforms, such as modular bioprocessing and continuous manufacturing technologies. The complexity of large molecule drug development also requires advanced analytical capabilities and expertise in process characterization, adding another layer of technical challenges. Additionally, workforce shortages in bioprocess engineering and regulatory compliance are impacting the ability of CDMOs to scale operations efficiently. Overcoming these challenges will be critical for ensuring sustainable growth and meeting the increasing demand for large molecule CDMO services.

What Is Driving the Expansion of the Large Molecule CDMO Market?

The growth in the large molecule CDMO market is driven by several factors, including the rising adoption of biologics, increasing biopharmaceutical investments, and advances in manufacturing technologies. The surge in demand for monoclonal antibodies, vaccines, and cell and gene therapies is propelling the need for specialized CDMO services that can handle complex biomanufacturing processes. The expansion of contract development partnerships between pharmaceutical companies and CDMOs is accelerating, as firms seek cost-effective and scalable solutions for drug production. Regulatory agencies are also playing a key role in driving market growth by establishing guidelines that promote quality, safety, and efficiency in biologics manufacturing. The increasing trend toward personalized medicine and precision biologics is encouraging CDMOs to invest in flexible manufacturing technologies, such as single-use systems and high-throughput screening platforms. Additionally, advancements in process automation, AI-driven analytics, and smart bioprocessing are enhancing efficiency and reducing production costs. As pharmaceutical companies continue to shift toward outsourcing to mitigate risks and optimize resources, the large molecule CDMO market is poised for sustained growth, shaping the future of biopharmaceutical manufacturing.

SCOPE OF STUDY:

The report analyzes the Large Molecule Drug Substance CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Contract Manufacturing Service, Contract Development Service); Source (Mammalian Source, Microbial Source, Other Sources); End-User (Biotech Companies End-User, CRO End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abzena
• AGC Biologics
• Avid Bioservices
• BioVectra
• Boehringer Ingelheim BioXcellence
• Catalent, Inc.
• Emergent BioSolutions
• Eurofins Scientific
• FUJIFILM Diosynth Biotechnologies
• JHL Biotech
• KBI Biopharma
• Lonza Group
• Recipharm AB
• Rentschler Biopharma SE
• Samsung Biologics
• Siegfried Holding AG
• Syngene International
• Thermo Fisher Scientific Inc.
• Wuxi AppTec
• WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Large Molecule Drug Substance CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Shift Toward Biologics and Biosimilars Expands Addressable Market Opportunity for Large Molecule CDMOs
  • Escalating Complexity of Biologic Drug Substances Strengthens Business Case for Specialized CDMO Capabilities
  • Rising R&D Investment in Monoclonal Antibodies Spurs Demand for Large Molecule Manufacturing Partnerships
  • Growing Pipeline of Cell and Gene Therapies Propels Growth in Large Molecule CDMO Collaborations
  • Outsourcing Trends Among Small and Mid-sized Biopharma Drives Adoption of End-to-End CDMO Services
  • Regulatory Focus on GMP Compliance Throws the Spotlight on Quality-Centric CDMO Partners
  • Accelerated Drug Development Timelines Generate Demand for Agile and Scalable CDMO Infrastructure
  • Capacity Expansion Initiatives by Leading CDMOs Sustain Growth in Contract Manufacturing Capabilities
  • Biotech Startup Ecosystem Growth Expands Market Opportunities for Specialized Large Molecule CDMOs
  • Strategic Partnerships and Licensing Deals Strengthen the Business Case for Outsourced Drug Substance Manufacturing
  • Technological Advancements in Upstream and Downstream Processing Drive Efficiency and Quality in CDMO Operations
  • Integration of Single-Use Bioreactors and Modular Facilities Drives Adoption of Flexible Manufacturing Solutions
  • Increasing Focus on Sustainability and Green Manufacturing Practices Creates Opportunities for Differentiated CDMO Offerings
  • Rising Demand for High-Titer Expression Systems Accelerates CDMO Innovation in Bioprocess Optimization
  • Expansion of CDMO Presence in Emerging Markets Spurs Competitive Manufacturing Cost Advantages
  • Regulatory Harmonization and Fast-Track Approvals Propel CDMO Involvement in Global Biologic Launch Programs
  • Advanced Analytics and Digital Manufacturing Solutions Drive Operational Transparency and Process Control
  • Demand for Integrated Development-to-Commercialization Services Enhances CDMO Value Proposition
  • Growing Requirements for Process Characterization and Validation Expand Scope of CDMO Offerings
  • Increasing Importance of Cold Chain Logistics Infrastructure Strengthens CDMO Engagement Across the Supply Chain
  • Pandemic Preparedness and Vaccine Manufacturing Initiatives Spur Investment in Large Molecule CDMO Capacity
  • Shift Toward Personalized Biologic Therapies Drives Demand for Customizable CDMO Platforms
  • High Cost of In-House Biologics Infrastructure Strengthens Economic Case for CDMO Engagement
  • Competitive Differentiation Through Specialized Capabilities in ADCs and Fusion Proteins Propels Market Leadership
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Large Molecule Drug Substance CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Contract Manufacturing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Contract Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Mammalian Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Microbial Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Microbial Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Microbial Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for CRO End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for CRO End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for CRO End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION